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was performed. Cronbach’s alpha coefﬁcients and Pearson’s
product moment correlations were calculated to estimate relia-
bility. To establish construct validity, correlation coefﬁcients
were calculated between the subscales and vitality, well-being,
treatment satisfaction, and/or baseline glycosylated hemoglobin
(HbA1c). Standard errors of measurement (SEMs) were calcu-
lated to estimate minimal important difference. RESULTS: In
both studies: 1) factor analysis conﬁrmed the factor structure of
the four subscales with the exception that the “sleepiness or
drowsiness” item loaded with the Fatigue subscale items rather
than the Cognitive Distress items; 2) test-retest reliability (all
>0.68) and Cronbach’s alpha coefﬁcients (all >0.79) were accept-
able; 3) associations between subscales and other patient-
reported outcomes measures and/or HbA1c were signiﬁcant (p <
0.05) and in the hypothesized directions; and 4) SEMs were
approximately 0.5 on a 1 to 5 scale. CONCLUSION: Prelimi-
nary validation indicates that the Cognitive Distress, Fatigue,
Hyperglycemia, and Hypoglycemia subscales are potentially reli-
able and valid individual measures for use in clinical trials eval-
uating antihyperglycemic medications in patients with type 1 or
type 2 diabetes.
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HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES
MELLITUS: RELATIONSHIPS IN A CROSS-SECTIONAL STUDY
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OBJECTIVES: This study reports relationships between two
instruments of health status and an instrument of quality of life
(QoL) in a cross-sectional study among patients with Type 2 Dia-
betes Mellitus (T2DM). METHODS: Of generic health status
(SF-12 and EuroQoL EQ-5D), and diabetes-speciﬁc QoL (Audit
of Diabetes Dependent Quality of Life–ADDQoL). Patient
reported data were merged with retrospective clinical data
including A1C, comorbidities, diabetes complications score,
BMI, and others, from electronic medical records. RESULTS:
Usable response rate was 44.3% (n = 385). Mean A1C of respon-
dents was 7.2 (+1.4), mean diabetes duration was 10.2 (+9.1)
years, and 62.1% were obese (BMI >30). About 49% of respon-
dents were on oral medications only, 31.7% on oral medications
and insulin, and 9.4% on insulin only. Spearman correlations of
the EQ-5D were 0.640 with the SF PCS-12, 0.534 with the SF
MCS-12, and 0.316 with the ADDQoL (all p < 0.001). Insulin
use and diabetes-related complications were signiﬁcantly associ-
ated with poorer scores on all measures. Only ADDQoL scores
were signiﬁcantly better among those with the ADA recom-
mended A1C level <7.0 (p = 0.002). Nearly 73% respondents
reporting moderate problems with mobility and usual activities
on the EQ-5D were clinically obese. Obesity signiﬁcantly
impaired SF-12 scores but not ADDQoL scores. A path analytic
model relating SF-12 scores with EQ-5D and ADDQoL scores
had good ﬁt (Chi sq. = 1.32, p = 0.250; TLI = 0.99; RMSEA =
0.03). CONCLUSION: All three measures discriminated on the
basis of diabetes treatment group and number of complications.
Health status was impaired by obesity in T2DM. Those patients
with poorer glycemic control had lower scores on the disease-
speciﬁc QoL instrument. The health status and QoL instruments
used in the study appeared to measure different constructs, con-
ﬁrming past recommendations about their complementary use in
diabetes populations.
DIABETES-PATIENT—Reported Outcomes
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OBJECTIVES: To compare self-report measures of medica-
tion adherence with claims-based measures of adherence.
METHODS: A mail survey was conducted of persons with dia-
betes in the Henry Ford Health System in 2006. Prescription
claims were obtained for survey respondents, and the analyses
were conducted with 932 persons who were using at least two
oral medications for diabetes. The self-reported measures of
adherence included a six-category self-rating of adherence which
ranged from “never” to “all of the time” and a visual analog
scale (VAS) wherein patients marked the percentage of time that
they followed the medication regimen as directed The claims-
based measure was the continuous measure of availability
(CMA) reported as a scale from 0 to 100%. Two dichotomous
measures of adherence were created: CMA-80 (CMA cut at
80%); VAS-80 (VAS cut at 80%). RESULTS: The VAS and CMA
demonstrated a linear relationship in the expected direction with
the self-selected categories for medication adherence. The mean
VAS scores ranged from 62.4% to 98.1% across the categories
(F = 180.4, p < 0.001), and the CMA ranged from 66.1% to
85.4% (F = 15.8, p < 0.001). The VAS had a moderate correla-
tion with the CMA (r = 0.25). The mean (±SD) for the VAS and
CMA were 95.5 (±10.4) and 83.2 (±15.9), respectively. For dif-
ference scores (VAS minus CMA), 33.5% of respondents had a
VAS that was at least 1 SD higher than CMA. When comparing
the VAS-80 to the CMA-80, the area under the ROC curve was
0.54 (2.3% were categorized as adherent by CMA-80, but non-
adherent by VAS-80; 30.2% were categorized as non-adherent
by CMA-80, but adherent by VAS-80). CONCLUSION: Self-
reported adherence to medications by patients with diabetes is
moderately correlated with claims-based estimates. However,
about one-third of respondents will have a VAS that is signiﬁ-
cantly higher than CMA.
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OBJECTIVES: To evaluate medication adherence of select lipid
lowering and oral anti-diabetic medications in diabetic patients
during the Medicare Part D beneﬁt coverage gap. METHODS:
This was a retrospective evaluation of pharmacy claims data-
base. The evaluation consisted of standard Medicare Part D
beneﬁt patients at an 185,000 member managed care organiza-
tion during January 1, 2006 through November 30, 2006. Study
patients included anyone who encountered claims for both a 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin) and an oral (PO) anti-diabetic medication during January
2006, and reached the coverage gap by November 30, 2006.
Patients were excluded if they subsequently experienced cata-
strophic coverage or did not reach the coverage gap during 2006.
Medication adherence was measured using pharmacy claims
data to calculate medication possession ratios (MPR). A descrip-
tive comparison of MPR during “pre-coverage gap days” and
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“coverage gap days” was conducted for the study population. A
MPR of ≥0.8 was considered adherent. RESULTS: Of approxi-
mately 13,000 standard Medicare Part D patients, 189 had
claims for both a statin and a PO anti-diabetic during January
2006, and subsequently experienced the coverage gap. The
number of patients reaching the “doughnut hole” or coverage
gap in a given month ranged from 4 to 41, starting in April. The
average “pre-gap” and “gap” periods were 242 days and 123
days, respectively. The average MPR for PO anti-diabetics during
the “pre-gap” period was 24% higher than during the “gap”
(0.92 vs. 0.70). For the statins, there was an 18% decrease in
the average MPR between the “pre-gap” period and the “gap”
period (0.87 vs. 0.72). CONCLUSION: The overall medication
compliance (i.e. MPR) of statins and oral anti-diabetics
decreased during the 2006 Medicare Part D beneﬁt coverage gap
period. On average, patients became more non-adherent with
their statin and oral anti-diabetic therapies during the “gap”
period.
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OBJECTIVES: This study sought to evaluate the impact of con-
verting to insulin administration with an insulin aspart analog
pen from vial/syringe on medication adherence among type 2
diabetes patients. METHODS: A pre-post conversion approach
was adopted using an integrated medical and pharmacy claims
database from >50 managed care health plans in the United
States. Adults diagnosed with type 2 diabetes who converted to
insulin aspart pen therapy (NovoLog® FlexPen®) [index event]
from either human or analog insulin vials between July 2001 and
December 2002 with no prior use of FlexPen® for six months
were identiﬁed. Medication adherence in the pre and post-index
periods was measured using medication possession ratio (MPR).
Paired t-test was performed to test the statistical differences in
adherence rates. RESULTS: Data from 670 patients (prior analog
insulin vial/syringe users: 328; human insulin vial/syringe users:
342) newly treated with FlexPen® were analyzed. Mean patient
age was 45.7 years (SD: 13.8 years) and 50.8% were male. Upon
initiating FlexPen®, MPR was signiﬁcantly improved to 70%
(SD: 32%) in comparison to 65% (SD: 29%), p < 0.01, prior to
FlexPen® use. Previous human vial/syringe users [human pre-
mix users: 76% vs. 82%; p = 0.01, and NPH users: 66% vs.
70%; p = 0.02] showed the highest improvement in adherence
in the post-index period of 5 percentage points (71% vs. 76%;
p = 0.01), as compared to 4 percentage points (61% vs. 65%; p
= 0.01) among prior analog vial/syringe users [glargine users:
63% vs. 67%; p = 0.03, and analog pre-mix users: 59% vs. 63%;
p = 0.03]. CONCLUSION: Medication adherence to insulin
therapy based on MPR was signiﬁcantly improved following the
initiation of insulin aspart analog pen in type 2 diabetes patients.
Further analyses should evaluate the impact of improved adher-
ence on clinical health outcomes and associated costs.
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OBJECTIVES: To examine the relationship between eating
healthy foods and exercising regularly on physical health (PH),
mental health (MH), and perceived health status (PHS) among
type II diabetics. METHODS: The 2005 Center for Disease
Control and Prevention’s Behavioral Risk Factor Surveillance
System, a cross-sectional survey, was utilized. Respondents were
considered type II diabetics if diagnosis occurred minimally at
age 30. Eating healthy foods was deﬁned as eating at least 5 serv-
ings of fruits and vegetables daily. Exercising regularly was
deﬁned as meeting the recommendations for moderate and/or
vigorous exercise. Due to impact on quality of life we included
demographics, socioeconomic status, comorbidities, diabetic
complications, and insulin use as covariates. Poisson regressions
were used to compare the monthly number of PH or MH days
associated with eating healthy foods and exercising regularly.
Logistic regression determined the association between PHS
(good versus poor) and eating healthy foods or exercising regu-
larly. RESULTS: Among 21,590 type II diabetics identiﬁed, the
majority were Caucasian, older, urban, hypertensive, and did not
meet recommendations. Eating 3–4 servings of fruits and veg-
etables was associated with 0.1 (4.4%) and 2.9 (17.6%) more
days in which PH and MH was good compared to 5 servings (p
= 0.0113 and p < 0.0001). Consuming 1–2 servings of fruit and
vegetables daily was associated with lower PHS (p < 0.0001).
No exercise was associated with 5.8 (34.0%) fewer days of good
PH (p < 0.0001), 3.6 (21.9%) fewer days of good MH (p <
0.0001), and 8% lower odds of good PHS (p < 0.0001) com-
pared to people who exercise regularly. Annual household
income <$15,000 consistently was associated with poorer PH 
(p < 0.0001), MH, (p < 0.0001), and PHS (p < 0.0001). CON-
CLUSION: Glycemic effects from fruits and vegetables may con-
tribute to more PH and MH days for 3–4 daily servings
compared to 5. Causation cannot be inferred from these results
due to its cross-sectional and observational nature.
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OBJECTIVES: The risk of developing cardiovascular and other
life threatening diseases is strongly linked to increased body
weight. This is particularly relevant to people with type 2 dia-
betes (T2D) in whom over 80% are overweight. Limited data
exist on the impact on Health Related Quality of Life (HRQOL)
of Body Mass Index (BMI) for people with type 2 diabetes. The
aim of this study was to characterize the impact of BMI on
HRQOL for people with and without T2D in England.
METHODS: Data from the Health Survey for England 2003
(HSE03) was evaluated. HSE03 consisted of a stratiﬁed random
sample designed to provide data about the general population
living in private households in England. Observations for 13,233
non-diabetic patients and 461 patients with T2D were included.
HRQOL was measured using the EQ-5D. Overall HRQOL dif-
ferences were investigated using t-tests. Analyses of variance
